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Abstract
Background: High levels of patient adherence to antimalarial treatment are important in ensuring drug effectiveness. To
achieve this goal, it is important to understand levels of patient adherence, and the range of study designs and
methodological challenges involved in measuring adherence and interpreting results. Since antimalarial adherence was
reviewed in 2004, there has been a major expansion in the use of artemisinin-based combination therapies (ACTs) in the
public sector, as well as initiatives to make them more widely accessible through community health workers and private
retailers. These changes and the large number of recent adherence studies raise the need for an updated review on this
topic.
Objective:We conducted a systematic review of studies reporting quantitative results on patient adherence to antimalarials
obtained for treatment.
Results: The 55 studies identified reported extensive variation in patient adherence to antimalarials, with many studies
reporting very high adherence (90–100%) and others finding adherence of less than 50%. We identified five overarching
approaches to assessing adherence based on the definition of adherence and the methods used to measure it. Overall,
there was no clear pattern in adherence results by approach. However, adherence tended to be higher among studies
where informed consent was collected at the time of obtaining the drug, where patient consultations were directly
observed by research staff, and where a diagnostic test was obtained.
Conclusion: Variations in reported adherence may reflect factors related to patient characteristics and the nature of their
consultation with the provider, as well as methodological variations such as interaction between the research team and
patients before and during the treatment. Future studies can benefit from an awareness of the impact of study procedures
on adherence outcomes, and the identification of improved measurement methods less dependent on self-report.
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Introduction
While considerable progress has been made in the last decade to
reduce malaria morbidity and mortality, malaria continues to
cause more than 200 million cases and more than 600,000 deaths
per year [1]. The vast majority of deaths occur among children
under five in Africa, though many other parts of the world are also
affected. Malaria is entirely preventable and treatable, but if
treatment is delayed or ineffective, the parasite burden may
rapidly increase and cause severe malaria, which has a case fatality
rate of 10–20% even among those receiving treatment [2].
Resistance of parasites to antimalarials, exacerbated by their
widespread and indiscriminate use, threatens the effectiveness of
malaria treatment.
In order for antimalarial treatment to be effective, multiple steps
must occur [3–4]. The patient must promptly seek care, the
correct diagnosis must be made; the correct drug and dose must be
recommended; the drug must be efficacious, of good quality and in
stock; the patient must receive or purchase the correct dose; and
the correct dose must be taken with correct timing until all doses
are complete. Not only can incomplete dosage result in treatment
failure, but it may arguably contribute to the spread of resistance
[5–6]. Sub-therapeutic treatment can result in recrudescence and
select for resistant parasites [7]. Patient adherence, defined as
correctly taking the full therapeutic course of treatment, is thus a
critical step in ensuring antimalarial effectiveness and reducing
malaria mortality.
To achieve this goal, it is important for policymakers to
understand levels of patient adherence to antimalarials, how they
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vary by context, and how adherence can be improved. However,
studies measuring patient adherence encounter substantial meth-
odological challenges, such as selection of appropriate definitions
of adherence and appropriate measurement methods. This results
in a broad diversity of study designs which, along with the wide
range of study contexts and different antimalarial drugs, can
challenge interpretation of adherence results.
The use of antimalarial drugs was last reviewed by Yeung and
White in 2004 [8]. Of the 22 studies they identified in Africa, Asia
and South America that reported quantitative data on patient
adherence, only five assessed adherence to artemisinin-based
combination therapies (ACTs), and only eight studies, mostly
household surveys, measured adherence to antimalarials obtained
through community health workers or drug retailers. Since
publication of this review, there has been a major expansion of
the availability of ACTs, which have been shown to be efficacious
and may reduce the spread of resistance in low transmission
settings [9–12]. Due to the development of resistance to older
antimalarials, such as chloroquine and sulfadoxine pyrimethamine
(SP), ACTs have become the first-line treatment for Plasmodium
falciparum malaria in the public sector in most malaria-endemic
countries. In addition, a growing number of initiatives to increase
ACT use through community health workers and private sector
providers have been implemented [13]. Furthermore, a large
number of new studies assessing adherence to antimalarials,
particularly to ACTs, have been conducted in the last nine years,
raising the need for an update on this topic.
Here, previously reviewed and recent studies providing quan-
titative results on adherence to antimalarials obtained for
treatment are analysed. We examine how results vary by definition
of adherence and key methodological characteristics, and we
present the studies’ own findings on factors associated with
adherence. We emphasize challenges in measuring adherence,
avoiding bias, and implications for future research.
Methods
Studies included in this review were identified by three methods.
First, a systematic literature search was conducted on PubMed
using MeSH and free text terms as follows: (Medication
Adherence (MeSH) or Patient Compliance (MeSH) or compliance
or adhere*) and (Antimalarials (MeSH) or antimalarial*). Second-
ly, reference lists from studies and reviews identified were searched
manually for relevant studies. Finally, researchers known to be
currently active in the field were contacted.
Studies that were clearly irrelevant were immediately discarded,
and abstracts and manuscripts of the remaining studies were
examined in detail to determine relevance. Published studies that
provided quantitative data on patient adherence to antimalarials
obtained for treatment of malaria were included in this review.
Where papers employed both quantitative and qualitative
methods, only the quantitative results are reported here. Studies
were included from all parts of the world in any language utilizing
various study designs, including household surveys and clinical
trials examining the effectiveness of supervised versus unsupervised
treatment that specifically reported data on adherence in the
unsupervised arm. Studies assessing adherence to antimalarials
obtained for prophylaxis, and effectiveness studies that did not
report data on adherence were excluded. Manuscripts of studies
meeting inclusion criteria were read in detail and data on study
settings, objectives, study design, definitions of adherence, methods
of assessing adherence and results were systematically reviewed
and abstracted into a database.
Results
The initial literature search using PubMed identified 1340
studies (Figure 1). In total, 49 studies were retained from the initial
search. Many of the excluded studies referred to antimalarials
obtained for prophylaxis or treatment of conditions other than
malaria. Manual examination of reference lists and personal
communication with other researchers in the field identified six
additional studies, making a total of 55 studies.
Characteristics of studies included
Three main types of studies were identified: descriptive studies,
interventions to improve adherence, and studies with clinical
outcomes as a primary endpoint (Tables 1–3). While there is
clearly some overlap between types, studies were categorised as
descriptive except for those that described an intervention to
improve adherence or simultaneously measured clinical outcomes
and patient adherence. Distinguishing studies with clinical
outcomes is helpful, as they were often conducted under relatively
controlled conditions, or with relatively intensive follow-up, which
may have influenced adherence results.
More than half of the 55 studies were descriptive (30 studies)
[4,14–42]. The majority of these (21 studies) were observational
follow-up studies [14–34], where patients obtaining a drug were
visited at their home or returned to the drug outlet after a specified
number of days, at which time adherence data were collected.
While most follow-up studies were prospective, two studies
retrospectively identified patients to follow-up for adherence
assessments [21,25]. Several of these studies were part of larger
studies that included an intervention (e.g. use of community health
workers [15,24] or subsidization of ACTs in private retail outlets
[16]), but did not provide information on the impact on adherence
through pre and post or control group comparisons, so the studies
were categorised as ‘‘descriptive’’ in terms of their assessment of
adherence. Eight studies used household surveys to collect
descriptive data [35–42], and one study used both household
survey and follow-up methods [4]. In these household surveys,
households in selected areas were visited without prior knowledge
of who had obtained antimalarial drugs, and interviews were
conducted about episodes of illness occurring in the weeks prior to
the survey, treatment obtained, and adherence.
Figure 1. Literature search results.
doi:10.1371/journal.pone.0084555.g001
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Thirteen studies evaluated interventions to improve adherence
[43–55]. Of these, seven were randomized controlled trials (RCTs)
[44,46–47,50–51,54–55], two were controlled pre- and post-
intervention studies [43,45], two were uncontrolled pre- and post-
intervention studies [48–49], and two were post-intervention only
adherence assessments [52–53]. Follow-up methods were used by
eight of the thirteen intervention studies, while the remaining four
used household surveys. The interventions included new packag-
ing with and without training, including pre-packaging of two
component drugs together and pictorial inserts to packaging
[47,50–53,55], as well as dispenser training of shopkeepers [48–
49] or community health workers [54]. Ansah et al. (2001) [44]
conducted an RCT of chloroquine tablets for children compared
to chloroquine syrup, while Denis et al. (1998) [45] evaluated
videos and posters as community health education strategies to
improve adherence to a 7-day regimen of quinine + tetracycline.
The third type of studies, those assessing clinical outcomes as a
primary endpoint in addition to reporting patient adherence,
included seven RCTs comparing effectiveness and adherence of
different drug regimens [56–60] or supervised versus non-
supervised treatment [61–62], and four uncontrolled studies also
assessing effectiveness and adherence [63–66], all of which
employed follow-up methods. In addition, a prospective open
cohort study examined the association of previous compliance with
antimalarials for malaria caused by P. falciparum or P. vivax and
occurrence of malaria during follow-up [67].
Of the 55 studies, 40 took place in Africa, 11 in Asia, and four in
Latin America. Subjects included all age groups in 25 studies, only
children under five in 19 studies, both children under five and
older children in an additional seven studies, and only adults in
four studies. Most studies assessed adherence to antimalarials
taken to treat infection with P. falciparum, with five studies focusing
on treatment for P. vivax [21,25,31,51,62], and three studies on
treatment for both species [32,66–67]. Most studies assessed
adherence to treatment obtained in health facilities or malaria
clinics. Four follow-up studies evaluated adherence to drugs
obtained from community agents [15,24,28,54] three took place in
the context of complex humanitarian emergencies [17–18,26], and
three were conducted from private drug shops [16,30,45]. Most
household surveys reported adherence to antimalarials obtained
from both public and private sectors, except for four that focused
on interventions to improve adherence to antimalarials obtained
from drug shops [48–49] or community health workers [36,53].
Patient adherence to more than one drug regimen was assessed
in 12 studies, while 43 studies reported adherence to a single drug
(Tables 1–3). Adherence to ACTs was assessed in 26 studies.
Artemether-lumefantrine (AL) was the ACT in 18 of these studies,
with two of these 18 also reporting adherence to artesunate-
amodiaquine [36,60]. Other ACTs evaluated included two
additional studies of artesunate-amodiaquine [14,20], as well as
SP + artesunate [17,23] and artesunate + mefloquine [52,63–64].
Non-artemisinin-based combinations featured in 13 studies
(chloroproguanil-dapsone (CPD) [57–58], quinine + doxycycline
or tetracycline [45,59,67], chloroquine + SP [26,40,47], SP +
amodiaquine [65] and, for treatment of P. vivax malaria,
chloroquine + primaquine [25,31–32,51,62,66–67]). Adherence
to chloroquine and other monotherapies was assessed in 20
studies.
Definitions of adherence and measurement methods
The 55 studies reviewed here employed a wide range of
definitions and methodologies. Adherence was measured by
questionnaires containing varying detail about how and when
drugs were taken (self-report); physical counts of tablets remaining
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in packaging or dispensing envelopes (pill counts) and volumetric
measurement of syrups; pill containers with electronic caps that
record the date and time of each opening (electronic pill boxes);
assays for drug levels in biological samples; and composites of these
methods.
At least one approach used in 52 of the 55 studies could be
classified under one of five overarching approaches defined for the
purpose of this review, based on both the nature of adherence
required and the method used to measure adherence (Table 4).
‘‘Completed treatment’’ identifies individuals who said they
completed treatment. ‘‘Verified completed treatment’’ refers to
reported completed treatment that is corroborated by a pill count.
‘‘Timely completion’’ refers to patients reporting that they
completed each dose at an appropriate time. ‘‘Verified timely
completion’’ identifies those reporting timely completion with a
pill count to confirm that no tablets were left. Lastly, ‘‘biological
assay’’ refers to detection of sufficient levels of drugs in biological
samples.
Correct timing of doses, involving the correct dose, frequency,
and duration, was required in 22 studies (‘‘timely completion’’ and
‘‘verified timely completion’’), 11 of which were studies of ACTs.
However, there was considerable variation in which intervals were
considered ‘‘correct’’, ‘‘recommended’’ or ‘‘prescribed’’. Several
studies calculated the expected time of each dose per the
manufacturer’s instructions and allowed an interval of several
hours on either side [22–23,28], while other studies required the
correct dose to be taken on each day specified, or for AL twice per
day for three days [15,18,33,61], and other studies did not report
exactly what was considered correct. This is in contrast to
assessments of ‘‘completed treatment’’ and ‘‘verified completed
treatment’’, which did not require correct timing of doses.
Furthermore, many studies reported in their methods that drug
packaging was inspected, but only 21 studies specifically incorpo-
rated pill counts into adherence definitions, requiring self-reported
adherence verified by empty packages or the expected number of
remaining pills (‘‘verified completed treatment’’ and ‘‘verified
timely completion’’).
Adherence results
The studies reported a very wide range of results for the
percentage of patients adherent, ranging from 1.5% to 100%
across different studies and settings. Below we explore how the
results varied firstly by the approach to assessing adherence and
data collection, secondly by antimalarial and outlet type, and
thirdly by the nature of the interaction between patients and
dispensers or researchers during the study. Scatter plots are used to
facilitate the identification of general patterns in these results.
Finally we present the studies’ own findings on factors found to be
associated with adherence in multivariate models.
(i) Variation by approach and data collection method
Figure 2 shows a comparison of adherence results by the five
approaches. The plot includes multiple points from studies which
used more than one approach to report adherence. Studies that
did not use any of the five approaches were not plotted [4,37,56].
In addition, when results of adherence to the same drug were
reported from more than one study site within the same country,
the weighted average of these sites was plotted [35,45]. For
intervention studies, only baseline results were plotted in order to
represent standard practice; thus, two studies were not plotted
since they provided adherence results post-intervention only [52–
53]. When multiple non-overlapping degrees of adherence were
used (such as definitely non-adherent, probably non-adherent, probably
adherent), the most adherent level was considered the proportion
adherent for the purpose of Figure 2.
Overall, it does not appear that using stricter approaches
involving correct dose timing (‘‘timely completion’’ and ‘‘verified
timely completion’’) or requiring pill counts in addition to self-
reported histories (‘‘verified completed treatment’’ and ‘‘verified
timely completion’’) are associated with lower adherence, but this
does not account for differences in contexts and methodologies.
However, among studies of AL, adherence by ‘‘verified timely
completion’’ (38.7%–65%) [18,28–29] was lower compared to
Figure 2. Percentage of patients classified as adherent, by
Approach to assessing adherence.
doi:10.1371/journal.pone.0084555.g002
Table 4. Approaches to assessing patient adherence across studies.
Approach Definition Method Number of studies1
Completed treatment Patient completed treatment Self-report 28
Verified completed
treatment
Patient completed treatment Self-report and pill count 10
Timely completion Patient exactly followed instructions in terms of dose, frequency and duration Self-report 12
Verified timely
completion
Patient exactly followed instructions in terms of dose, frequency and duration Self-report and pill count 11
Biological assays Sufficient levels of drug(s) in biological samples Biological assays 4
Unique approaches Various Various 11
1All studies are included if adherence is reported by at least one of these five approaches (n = 52 studies) and are included more than once if multiple approaches were
used.
doi:10.1371/journal.pone.0084555.t004
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‘‘timely completion’’ (88.3%–100%) [15,22,33], except in studies
where the research team enrolled patients at the time the drug was
obtained and likely had a more significant research presence than
in other studies (90% and 93%) [19,61]. Similarly, adherence to
AL by ‘‘verified completed treatment’’ (64.1%–83%) [16,24,27,
29,60] tended to be lower than for ‘‘completed treatment’’ (67%–
100%) [22,28,36,38,57–58], with the exception of two household
surveys without pill counts with adherence of 47% [41,46].
Household surveys, which all used the ‘‘completed treatment’’
approach and assessed adherence from both public and private
community sources, tended to have lower adherence results than
studies with other designs, particularly studies with primary clinical
outcomes (Tables 1–3). In addition, studies plotted before
implementation of an intervention had lower adherence for all
approaches, as is particularly evident in the community-based
interventions by Marsh et al. (1999, 2004) and Winch et al. (2003)
and the private-sector follow-up study by Denis et al. (2008); this
may be because most of the interventions included in the review
are older studies and the interventions (e.g. pre-packaging of
drugs) have become a standard part of antimalarial treatment used
in the newer studies.
Among studies using unique approaches, two studies used
electronic pill boxes (Medication Events Monitoring Systems –
MEMSTM) to measure adherence [34,57]. In the study by Bell et
al. (2009) adherence by self-report (‘‘completed treatment’’) was
100% for AL and 99.2% for CPD, but by the electronic pill boxes,
adherence was 92% for AL and 91% for CPD. Similarly, in the
study by Twagirumukiza et al. (2010), adherence to quinine tablets
was 100% by both self-report (‘‘verified timely completion’’) and
pill count (no pill boxes had pills remaining), but only 78% of
patients took at least 80% of the doses based on the electronic pill
box data [34].
Results using biological assays to assess adherence were high
(above 90%), but this accounted for only a few studies [15,51,64].
Qingjun et al. (1998) evaluated a packaging intervention to
improve adherence to chloroquine + primaquine marked with
phenobarbital to detect concentrations in plasma, while Na-
Bangchang et al. (1997) measured adherence to artesunate +
mefloquine by whole blood mefloquine concentrations based on a
reference interval [64]. Similarly, Congpuong et al. (2010) used
both whole blood mefloquine concentrations and plasma concen-
trations of primaquine [63] to detect adherence to artemether +
mefloquine + primaquine. One additional study (Shwe et al., 1998)
also found high adherence of 99.5%, but was not included in the
plots because adherence to artesunate + mefloquine was only
reported after implementation of a co-packaging and training
intervention; in this study, tablets of quinine and chloroquine were
added to the regimen as markers for detection by urine assays. Five
other studies measured plasma levels of lumefantrine using HPLC
with mass spectrometry or UV detection [19,33,57,60–61], but
adherence was not reported on the basis of these assays. Median
lumefantrine concentrations were not significantly different
between patients who were or were not considered adherent by
self-report (‘‘completed treatment’’ and ‘‘timely completion’’) or
self-report with pill count (’’verified timely completion’’).
(ii) Variation by antimalarial type and outlet type
The pattern of adherence results between antimalarials was not
clear. Across all approaches and by ‘‘completed treatment’’
adherence to AL (47%–100%) [22,28,36,38,41,46,57–58] was
higher than both adherence to monotherapies estimated from
Figure 3. Percentage of patients classified as adherent, by patient interaction with research staff and dispensers.
doi:10.1371/journal.pone.0084555.g003
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household surveys (3.7%–34%) [35,39–40,42,48–49] and adher-
ence to longer primaquine regimens for the treatment of vivax
malaria (25%–85%) [21,25,31–32,51,62,66–67]. Adherence to AL
by ‘‘verified completed treatment’’ (64.1%–83%) [16,24,27,29,60]
was lower than adherence to artesunate-amodiaquine (77%–91%)
[14,60] and chloroquine+SP (96%) [26]. However, adherence to
AL by ‘‘timely completion’’ was high in three studies (88.3%–
100%) [15,22,33] in contrast with studies of SP + amodiaquine
(37.7%) [65] and SP + artesunate (76.6%) [23]. By ‘‘verified timely
completion’’ adherence to AL was similar in three studies (38.7%–
Table 5. Factors associated with adherence in multivariate models (p,0.05 or 95% confidence interval crosses the null).
Factors Studies
Demographics
Education
- Caretaker education at least 7 years Beer et al. 2009 [14]
- Attending some secondary school or beyond Cohen et al. 2012 [16]
- Higher education Onyango et al. 2012 [41]
Residence in one of two areas in study location Duarte et al. 2003 [67]
Age
- Respondent age 25-50 years versus less than 25 years Lawford et al. 2011 [27]
- Patient age 15 years or more versus less than 15 years Lawford et al. 2011 [27]
- Patient age less than 13 years Onyango et al. 2012 [41]
Ownership of radio Lemma et al. 2011 [28]
Higher household income Onyango et al. 2012 [41]
Simba et al. 2012 [33]
Treatment-seeking behaviour
Not having sought treatment at a public health facility Cohen et al. 2012 [16]
Respondent sought treatment within 24 hrs of symptom onset versus waiting longer Lawford et al. 2011 [27]
Delay of more than 1 day in seeking treatment after the onset of fever Lemma et al. 2011 [28]
Previous care sought Souares et al. 2008 [65]
Factors related to the consultation
Having received exact number of pills to complete treatment Beer et al. 2009 [14]
Reporting having been given instructions at the shop Cohen et al. 2012 [16]
Reporting that instructions given were clear Cohen et al. 2012 [16]
Attended Migowi HC (one of three study outlets) Mace et al. 2011 [29]
Package used as visual aid by dispenser to explain how to take the drug Mace et al. 2011 [29]
Received written instructions Pereira et al. 2011 [31]
Quality of history taking (i.e. nurses at the consultation asked questions about history, symptoms,
and previous care)
Souares et al. 2008 [65]
Behaviour
Took first AL dose at HC Mace et al. 2011 [29]
Taking AL with food or oil Simba et al. 2012 [33]
Knowledge and perceptions
Knowledge that only mosquitoes cause malaria Gerstl et al. 2010 [20]
Knowledge of malaria aetiology Khantikul et al. 2009 [25]
Respondent had seen the drug before Lawford et al. 2011 [27]
Being able to cite at least one correct instruction on how to take AL Lawford et al. 2011 [27]
Belief that malaria cannot be treated traditionally Lemma et al. 2011 [28]
Access to information about antimalarials Khantikul et al. 2009 [25]
Knowledge of the seriousness of the infection/knowing the species in mixed transmission areas Yepez et al. 2000 [66]
Satisfaction
Having an improved condition at follow-up Cohen et al. 2012 [16]
Lower expectation of getting malaria in the next 30 days Cohen et al. 2012 [16]
Did not report dislikes/side-effects to medication Lawford et al. 2011 [27]
Preference for AL Mace et al. 2011 [29]
Satisfaction with received information Souares et al. 2008 [65]
doi:10.1371/journal.pone.0084555.t005
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65%) [18,28–29] to adherence to other ACTs (39.4%–75%)
[17,20,23] and higher in two other studies (90%–93%) [19,61].
Although most studies evaluated adherence to antimalarials
obtained in the public sector, the two descriptive private sector
follow-up studies had low adherence, with Nshakira et al. (2002)
reporting adherence of 37.8% to chloroquine by ‘‘completed
treatment’’, and Cohen et al. (2012) describing adherence of 65.8%
to AL. Three household surveys [46,48–49] and one follow-up
study [45] assessing interventions in private drug stores and
surrounding communities also all reported adherence of less than
50%. Adherence where antimalarials were obtained from CHWs
in four studies using follow-up methods ranged widely from 1.5%–
100% [15,24,28,54], with a study of AL by Lemma et al.(2011) in
Ethiopia finding adherence of 38.7% by ‘‘verified timely
completion’’ and 73.5% by ‘‘completed treatment’’. In addition,
a study evaluating adherence to ACTs dispensed by CHWs
reported high adherence of 83%–97% by ‘‘completed treatment’’
in household surveys in three countries [36].
(iii) Variation by nature of interaction of patients with dispensers
and research personnel
We explored how adherence results varied depending on the
nature of the interaction reported between patients and their
dispensers, and between patients and research personnel.
Figure 3a–d shows how patient adherence (as assessed by any of
the five approaches) varied with four aspects of patient interaction
that we hypothesised might influence adherence results. As shown
in the first plot, patients in some studies were asked for informed
consent to participate in the study at the outlet upon obtaining the
drug, while patients in other studies were not asked for informed
consent until a later follow-up visit, having had several days to take
the drug (Figure 3a). Secondly, research staff in some studies
observed the consultation of the patient with the dispenser or
conducted the consultation themselves, while other studies did not
(Figure 3b). Studies where most patients obtained a malaria
diagnostic test prior to treatment were plotted in comparison to
studies where patients were not tested (Figure 3c). The fourth plot
compares studies where dispensers did and did not observe the
patient swallowing the first dose of the drug (Figure 3d). Results of
all studies that used one of the five approaches are plotted, as
described previously for Figure 2, except that for studies using
multiple approaches to assess adherence, only the most inclusive
approach reported was plotted (i.e. ‘‘completed treatment’’).
Studies could not be plotted if the nature of the patient interaction
for each of the four plots was not reported.
Figure 3a suggests that collecting informed consent from
patients at the outlet visit when the drug is dispensed can result
in higher adherence compared to requesting informed consent at
the time of the follow-up visit. Similarly there is an indication that
observation by the study team of patients’ consultations with
dispensers may influence patients to be more adherent (Figure 3b),
and that where patients were confirmed to have malaria with a
Table 6. Factors associated with non-adherence in multivariate models (p,0.05 or 95% confidence interval crosses the null).
Factors Studies
Demographics
Being male Achan et al. 2009 [56]
Pereira et al. 2011 [31]
Caretaker having different mother tongue to pharmacist Depoortere et al. 2004 [17]
Education
- Caretaker education (none versus some) Depoortere et al. 2004 [17]
- Lack of formal education Fogg et al.2004 [19]
Age
- Being a child under 5 Mace et al. 2011 [29]
- Being a child age 8–10 years versus 2–4 years Souares et al. 2008 [65]
Head of household profession (retailer/employee vs. farmer) Souares et al. 2008 [65]
Treatment-seeking behaviour
No fever reported Kalyango et al. 20131 [24]
Seeking care after 2 or more days Kalyango et al. 20131 [24]
Takeuchi et al. 20092 [62]
Factors related to the consultation
Treatment with oral quinine versus AL Achan et al. 2009 [56]
Being counselled about what to do in case of vomiting Kachur et al. 2004 [23]
Not understanding instructions Kalyango et al. 20131 [24]
Knowledge and perceptions
Caregiver’s perception that illness is not severe Kalyango et al. 20131 [24]
Satisfaction
Vomiting Achan et al. 2009 [56]
Kalyango et al. 20131 [24]
1Includes patients receiving Al only and AL plus antibiotics (treatment group not significant in multivariate analysis);
2Associated with non-adherence in the second week of primaquine treatment for P. vivax infection.
doi:10.1371/journal.pone.0084555.t006
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rapid diagnostic test (RDT) or blood smear prior to being
dispensed antimalarials, adherence was higher than among those
not tested (Figure 3c). There is also some indication that studies
where dispensers observed patients’ first dose had higher
adherence than those where the first dose was not observed,
although the pattern is less clear (Figure 3d).
(iv) Factors associated with adherence in multivariate models
Understanding the characteristics and behaviours associated
with patient adherence to antimalarials is vital to designing
interventions to improve appropriate use of ACTs. Twenty-four
studies used multivariate analysis to examine factors associated
with adherence: of these, 13 studies reported 30 factors
significantly associated with adherence in multivariate models,
nine studies found 12 factors associated with non-adherence, and
five studies reported not finding any factors significantly associated
with adherence or non-adherence [32,44,50,55,61]. While many
of the twenty-four studies tested similar factors, such as demo-
graphics, instructions given and patient knowledge, there was
substantial diversity in which factors were found significant.
Tables 5–6 show factors significantly associated with adherence
(Table 5) and non-adherence (Table 6), including demographics,
treatment-seeking behaviour, factors related to the consultation,
behaviour, knowledge and perceptions, and satisfaction. Factors
significantly associated with adherence in more than one study
included higher education [14,16,41], higher household income
[33,41], provision of better information on how to take drugs
[16,29,31], and knowledge about malaria and antimalarials
[20,25,27–28,66]. Factors significantly associated with non-adher-
ence in more than one study included being male [31,56], lack of
education [17,19], and vomiting [24,56]. There were contrasting
results for the effects on adherence of patient age and the number
of days after onset of symptoms that treatment was sought. Older
age of the patient was associated with adherence in one study [27]
and non-adherence in another [65], while two other studies found
younger age associated with adherence [41] and non-adherence
[29]. Similarly, Lemma et al. (2011) found that patients who waited
more than one day to seek care after onset of fever were more
likely to be adherent, but other studies showed that seeking care
within 24 hours of symptom onset was associated with adherence
[27], and waiting two or more days was associated with non-
adherence [24,62].
Discussion
Extensive variation was observed in patient adherence to
antimalarials, with many studies reporting very high adherence
(90–100%) and others finding clearly suboptimal adherence,
sometimes of less than 50%. This may be an important problem,
both in terms of clinical outcomes and also in the context of the
development of resistance to artemisinin in South-East Asia [68].
However, it is unclear how good adherence must be for ACTs to
be efficacious, and which features of adherence (such as correct
timing of dose intervals or taking each dose with a fatty meal)
matter most.
We identified five overarching approaches to assessing adher-
ence based on recall (‘‘completed treatment’’ and ‘‘timely
completion’’), recall and pill counts (‘‘verified completed treat-
ment’’ and ‘‘verified timely completion’’) and on biological assays.
By ‘‘completed treatment’’ and ‘‘verified completed treatment’’,
adherent patients were defined as completing the full course of
treatment though not necessarily following a specific schedule.
Whether these are appropriate approaches to assess adherence
should be considered in light of the pharmacology of the specific
drug: if the safety or efficacy of the drug is critically dependent on
the timing of the doses then it will be important to assess this when
evaluating adherence. As these approaches do not include the
spacing of the doses, it is possible for patients to have taken some
doses too close together or even to have taken all doses at one time
and still be considered ‘‘adherent’’, though such practices could be
of concern for drug safety and efficacy. Furthermore, there is
potential variation within each approach in what was considered
correct treatment, with some studies taking into account national
guidelines on the correct dose-for-weight that the patient should
have consumed and other studies assuming the correct amount
was obtained.
By ‘‘timely completion’’ and ‘‘verified timely completion’’,
adherent patients were defined as exactly following instructions in
terms of dose, frequency and duration according to their responses
to interview questions. As noted above, there was considerable
variation in definitions of ‘‘correct’’ timing, which may have
affected comparability within these approaches. More information
is needed on how precise time intervals between doses must be in
order for drugs to be efficacious. For example, the packaging of
various brands of AL states that the second dose should be taken
eight hours after the first dose, which would fall in the middle of
the night if the drug is obtained in the evening. In this situation it is
unclear whether a patient should still be considered adherent if
they take the drugs first thing the next morning instead.
The majority of the adherence studies used one or more of these
approaches relying primarily on self-reported drug histories, which
may be susceptible to recall and social desirability bias. Studies in
Tanzania and Cambodia found high levels of antimalarials
circulating in the blood among patients stating they had not
taken any drugs in the previous 28 days [69–70]. Patients may not
accurately recall information about the quantity of drugs taken.
Moreover, even if the precise time of obtaining the drug from the
provider is known, asking patients when each dose was taken is
problematic as they may not have had clocks available or may not
know or remember the exact time. Recall bias is likely to be higher
in data obtained from household surveys, where interviewers
frequently ask about drugs taken in the previous 14 days,
compared to follow-up studies, where recall time is usually 4–7
days. Even with short recall periods, patients may not correctly
remember details related to each dose. Cultural and demographic
factors may also affect the reliability of self-reported data [71]. For
example, in a study of the impact of the length of recall periods for
health surveys, different recall periods gave different results, and
these differences were shown to vary by income group [72].
To avoid being seen as ignorant or negligent, patients who are
aware of the expected behaviour may say they were adherent even
if they actually were not. A study by Peeters Grietens et al. (2010)
found that while 72% of patients reported taking the full course of
primaquine, only 49% claiming to take the full course had actually
received the full course according to records [21]. Likewise, Bell
and colleagues stated that self-reported data, which resulted in
100% adherence to AL and CPD in Malawi, was unreliable
compared to MEMSTM containers [57].
In order to reduce recall and social desirability bias, some
studies incorporated manual examination of drug packaging into
their definitions of adherence (‘‘verified completed treatment’’ and
‘‘verified timely completion’’). For studies of AL, these approaches
yielded lower adherence results than the equivalent approaches
without the pill counts (‘‘completed treatment’’ and ‘‘timely
completion’’). However, even results including pill counts may
over-estimate true adherence as removing pills from blister packs
does not guarantee that the pills were consumed. Similarly,
opening electronic pill boxes does not guarantee a dose was
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consumed. Patients may have ‘‘played’’ with their pill boxes,
opening them without removing pills, or alternatively, they may
also have removed multiple doses at one opening, either to
discard, consume, or save until the appropriate time.
Despite the limitations of self-reported and pill count approach-
es, Souares et al. (2008) suggested that self-reported data may be
more reliable and feasible than assays for drug levels, which
require invasive sample collection and complicated field logistics
[68]. Drug assays were rarely used for measuring adherence, and
their utility and appropriate role remains unclear. Adherence
evaluated by the detection of drugs in biological assays was very
high (90–100%) in four studies, but these studies assessed
adherence to drugs other than AL and involved close interaction
of the research staff with patients and in some cases extended
follow-up periods. The five studies that reported measuring
lumefantrine concentrations, but did not incorporate these assays
into adherence results, did not find significant differences in
lumefantrine concentrations between patients adherent and non-
adherent by self-report. This may have been due to the metabolic
variability of the study population, including age, pregnancy,
concomitant fat intake and other factors affecting drug absorption,
limiting the value of quantitative assessments of patient adherence
[73–74]. Methods of collecting blood samples, sample preservation
under field conditions, and details of the assays themselves are also
likely to affect results.
Regardless of the approach used for assessing adherence,
Hawthorne bias may occur if a patient’s awareness of being
studied positively influences medication-taking behaviour. Simi-
larly, if researchers observe patient consultations with the
dispenser, this may positively influence the care and advice
provided by the dispenser and/or patients’ attentiveness and
adherence to the treatment. In the studies reviewed here,
adherence was higher when informed consent was collected at
the time of obtaining the drug and to some degree when patient
consultations were directly observed (Figures 3a and 3b). While it
is reasonable to assume that medication-taking behaviour of
patients who are not aware they are being studied more accurately
reflects behaviour in real life contexts, these concerns must be
balanced by practical constraints, such as fulfilling other study
objectives and the need to obtain the patient’s consent and address
for follow-up visits.
Some specific patient-dispenser interactions might also be
expected to improve adherence. For example, confirmation of
diagnosis of malaria by an RDT or blood smear might increase
adherence if patients are more aware that they are suffering from
malaria, and if patients with confirmed malaria see a better
response to treatment than those who have other conditions.
Observing the first dose of treatment is another commonly
recommended practice and was found to be significantly
associated with adherence to AL in one study [29]. We found
some indication that malaria diagnosis was associated with higher
adherence in the reviewed studies, although the effect was less
marked for observing the first dose on adherence overall.
In addition to the approach to measurement and the nature of
the patients’ consultations, other factors often hypothesised to
influence adherence include patient characteristics, antimalarial
type and outlet type. However, it was not possible to discern clear
patterns across the studies reviewed. There was some evidence
from multivariate studies that patients who had higher socio-
economic status and were better educated or informed had higher
adherence. While there is some concern that the greater number
of tablets required for treatment with ACTs (i.e. 24 for an adult)
contributes to lower adherence compared to antimalarials
requiring fewer tablets, this was not clear in the studies reviewed
here. One potential explanation for this is that ACTs often come
in co-formulated or co-packaged blister packs, with different
coloured packages for each age or weight group. This is in contrast
to loose tablets dispensed into paper envelopes, which was often
the case for older antimalarials. Not only can the dispenser give
the patient the incorrect number of tablets, but the tablets may
need to be cut in half to achieve the appropriate doses, and it may
be more difficult for the patient to remember how many to take.
Secondly, more effective antimalarials such as ACTs may
encourage higher patient adherence; if drugs are perceived to be
ineffective, patients may use a drug briefly or not at all before
looking for a more effective alternative [8]. Finally, perceptions of
side-effects may cause variation in adherence across antimalarials,
with drugs such as chloroquine and quinine known to have more
common minor adverse effects than ACTs such as AL.
It was hard to assess variation across outlet types as of the 55
studies included, only five specifically evaluated adherence to
antimalarials from private drug shops [16,30,45,48–49] and five
from community health workers [15,24,28,36,54]. However, there
were some indications that adherence was relatively low from
private sector outlets, highlighting the need for more studies to
evaluate adherence to ACTs obtained in this sector and to design
interventions to ensure drugs are used appropriately. Interventions
to improve adherence that are currently being tested in the private
sector include the introduction of RDTs [75–76], new packaging,
SMS reminders to patients [77], and SMS reminders to drug shop
dispensers to encourage them to advise patients on the importance
of adherence [78].
Conclusion
The literature reports extensive variation in patient adherence
to antimalarials. The unsatisfactory patient adherence sometimes
reported to ACTs obtained in the public sector, and the current
dearth of data from the private sector, represent significant
challenges for maximising the impact of ACTs. Variations in
adherence may reflect factors related to patient characteristics and
knowledge, their treatment seeking behaviour, and the nature of
their consultation with the provider. However, methodological
variations between studies are also likely to be an important source
of variability in results, including the methods used for collecting
data, and any interaction between the research team and patients
before and during the treatment course. Future studies could be
strengthened by a greater awareness of the impact of study
procedures on adherence outcomes, and the identification of
improved measurement methods that are less dependent on self-
report.
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